We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$285M
AUM Growth
+$33.9M
Cap. Flow
-$13.6M
Cap. Flow %
-4.76%
Top 10 Hldgs %
67.96%
Holding
105
New
6
Increased
8
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.84M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$1.6M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$890K
4
ZIMV
ZimVie
ZIMV
+$642K
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$515K

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$7.16M
2
VKTX icon
Viking Therapeutics
VKTX
+$2.17M
3
LK
Luckin Coffee Inc. American Depositary Shares
LK
+$2.11M
4
ICLO icon
Invesco AAA CLO Floating Rate Note ETF
ICLO
+$1.25M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$876K

Sector Composition

Rank Sector Weight
1 Healthcare 30.38%
2 Materials 27.67%
3 Financials 18.32%
4 Communication Services 6.88%
5 Technology 3.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESGR
26
DELISTED
Enstar Group
ESGR
$2.41M 0.85%
7,500
– –
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.39M 0.84%
+34,000
New +$2.84M
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.06B
$2.36M 0.83%
52,368
– –
SNDX icon
29
Syndax Pharmaceuticals
SNDX
$2.02B
$2.35M 0.83%
122,144
+18,318
+18% +$378K
DMRC icon
30
Digimarc Corp
DMRC
$134M
$2.25M 0.79%
83,557
– –
MREO
31
Mereo BioPharma
MREO
$49.5M
$1.36M 0.48%
331,000
+95,000
+40% +$393K
RHP icon
32
Ryman Hospitality Properties
RHP
$7.99B
$1.29M 0.45%
12,000
– –
XBI icon
33
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$988K 0.35%
10,000
-4,000
-29% -$393K
EOLS icon
34
Evolus
EOLS
$377M
$933K 0.33%
57,570
-51,112
-47% -$714K
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$123B
$930K 0.33%
2,000
-1,000
-33% -$480K
DD icon
36
DuPont de Nemours
DD
$18.3B
$885K 0.31%
7,911
– –
KMB icon
37
Kimberly-Clark
KMB
$36B
$854K 0.3%
6,000
– –
IRWD icon
38
Ironwood Pharmaceuticals
IRWD
$635M
$853K 0.3%
207,033
-162,967
-44% -$876K
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.6B
$821K 0.29%
20,866
– –
LXRX icon
40
Lexicon Pharmaceuticals
LXRX
$1.06B
$785K 0.28%
+500,000
New +$890K
ROIV icon
41
Roivant Sciences
ROIV
$24.8B
$711K 0.25%
61,583
-1,417
-2% -$16.1K
MSFT icon
42
Microsoft
MSFT
$2.93T
$688K 0.24%
1,600
– –
CTVA icon
43
Corteva
CTVA
$58.4B
$680K 0.24%
11,563
– –
MDLZ icon
44
Mondelez International
MDLZ
$78.3B
$663K 0.23%
9,000
-5,000
-36% -$351K
ZIMV
45
DELISTED
ZimVie
ZIMV
$567K 0.2%
+35,750
New +$642K
AMZN icon
46
Amazon
AMZN
$2.66T
$559K 0.2%
300
– –
CNQ icon
47
Canadian Natural Resources
CNQ
$91.5B
$558K 0.2%
16,800
– –
XOMA
48
DELISTED
Xoma
XOMA
$522K 0.18%
19,722
– –
CLOX icon
49
Panagram AAA CLO ETF
CLOX
$309M
$500K 0.18%
19,572
– –
GOOGL icon
50
Alphabet (Google) Class A
GOOGL
$4.23T
$497K 0.17%
300
– –
1
2
3 4 5

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q3 2024 Portfolio in Review

As of Q3 2024, David M. Knott Jr held 105 positions worth $285M, up 14% from $251M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

David M. Knott Jr withdrew a net $13.6M in Q3 2024, closing 13 positions and reducing 23 holdings. Its most notable exit was Ligand Pharmaceuticals, an estimated $7.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 31% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in BioMarin Pharmaceuticals worth $2.39M.

  • David M. Knott Jr's largest Q3 2024 buy was BioMarin Pharmaceuticals: 34,000 shares worth $2.39M.
  • David M. Knott Jr added most to Janus Henderson AAA CLO ETF in Q3 2024, an estimated $1.6M increase.
  • David M. Knott Jr's biggest Q3 2024 reduction was Viking Therapeutics, cutting an estimated $2.17M.
  • David M. Knott Jr fully exited Ligand Pharmaceuticals in Q3 2024, selling an estimated $7.16M.
  • David M. Knott Jr's ten largest holdings make up 68% of its $285M portfolio in Q3 2024.
  • David M. Knott Jr opened 6 new positions and closed 13 in Q3 2024.
  • David M. Knott Jr's portfolio value rose 14% quarter-over-quarter to $285M.

Based on David M. Knott Jr's 13F filing for Q3 2024, filed 13 Nov 2024.